Latest Strategic Initiatives News

HiTech Group Australia Limited reported a steady half-year profit of $2.04 million for H1 FY26, maintaining a strong cash position and zero debt while navigating government spending cuts. The company declared a fully franked interim dividend of 4.5 cents per share.

The Australian Wealth Advisors Group (AWAG) reported a 46% rise in net profit before tax for the half-year ending December 2025, driven by strong growth in funds under management and strategic joint ventures.

Butn Limited has reported its fifth consecutive half-year of revenue growth, underpinned by a $100 million senior debt facility and expanding platform originations. Despite a statutory loss, the company’s operational momentum and strategic initiatives signal robust growth prospects.

Lindsay Australia Limited reported a robust 24.9% increase in revenue for the half-year ending December 2025, driven by its strategic acquisition of SRT Logistics and strong divisional performances. However, profit after tax declined 11.7%, reflecting competitive pricing and integration expenses.

Resolute Mining has outlined its 2026 production guidance targeting up to 275,000 ounces of gold and revealed ambitious plans to more than double output by 2028 through key African project expansions.

Nuix Limited has reported robust half-year results for 1H26, highlighted by a 148% increase in Nuix Neo Annualised Contract Value and a significant boost in profitability and cash flow.

thl reports an 11% rise in underlying NPAT for H1 FY26 and sets a bullish FY26 guidance, underpinned by strategic divestments and cost efficiencies.

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Contact Energy has issued over 51 million new shares at NZD 8.75 each, representing a 5.17% increase in its ordinary shares, aiming to strengthen its shareholder base through a carefully structured placement.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Boom Logistics has reported a record half-year revenue of $142.2 million for 1H FY26, alongside upgraded earnings guidance and an expanded share buy-back program, signalling strong operational momentum despite sector challenges.